MDACC
Welcome,         Profile    Billing    Logout  
 58 Trials 
55 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jurcic, Joseph G
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting
3
510
US
Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin
Arog Pharmaceuticals, Inc.
Newly Diagnosed FLT3 Mutated AML
11/22
11/24
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Recruiting
2/3
443
Europe, US, RoW
BLU-263, Placebo
Blueprint Medicines Corporation
Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome
06/28
06/28
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Japan, US
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults With AML

Recruiting
1
94
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
06/24
12/24
NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Recruiting
1
140
Europe, US
SEA-CD70, azacitidine, VIDAZA
Seagen Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
12/24
11/26
NCT05524857: Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Terminated
1
2
US
Fedratinib Oral Capsule 300 mg, Inrebic, Decitabine 20 mg/m2, Dacogen, Fedratinib Oral Capsule 400 mg
Joseph Jurcic, Bristol-Myers Squibb
Myeloproliferative Neoplasm
04/24
04/24
Daver, Naval
KB-LANRA- 1001, NCT05028751: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Terminated
1/2
24
Europe, US
Lanraplenib, LANRA, Gilteritinib, XOSPATA®
Kronos Bio
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/24
04/24
BEXMAB, NCT05428969: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Recruiting
1/2
181
Europe, US
Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto®
Faron Pharmaceuticals Ltd
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
12/24
12/24
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
218
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax
Aptose Biosciences Inc.
Relapsed or Refractory Acute Myeloid Leukemia
02/24
08/24
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Active, not recruiting
1/2
179
Europe, US
IMGN632
ImmunoGen, Inc.
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
12/24
12/25
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
ImmunoGen, Inc., Jazz Pharmaceuticals
Acute Myeloid Leukemia
12/24
12/24
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Japan, US
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Active, not recruiting
1
37
Europe, Japan, US, RoW
VOB560, S65487, MIK665, S64315
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
07/24
07/24
03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
04/25
12/25
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Recruiting
1
36
US
DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto
Kahr Medical
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
08/24
12/24
NCT05775406: Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Recruiting
1
70
US
KT-253
Kymera Therapeutics, Inc.
Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
11/24
11/25
NCT05986240: Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Recruiting
1
24
US
Danvatirsen, AZD9150, Danvatirsen + Venetoclax, Venclexta
Montefiore Medical Center, M.D. Anderson Cancer Center, Flamingo Therapeutics NV
AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/25
07/28
NCT05155709 / 2021-001165-21: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Active, not recruiting
1
14
Europe, US, RoW
siremadlin, HDM201, venetoclax, azacitidine
Novartis Pharmaceuticals, Novartis Pharma AG
Acute Myeloid Leukemia
05/24
05/24
Wang, Michael
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Recruiting
3
71
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
PRESent-3, NCT05789537: A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors

Recruiting
2
12
Europe, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia B With Inhibitor, Hemophilia B
09/25
10/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Recruiting
2
120
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia A, Hemophilia B
03/26
06/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
ONCT-808-101, NCT05588440: A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Recruiting
1/2
57
US
ONCT-808, Bridging Therapy
Oncternal Therapeutics, Inc
Relapsed/Refractory Aggressive B-Cell Malignancies
12/26
12/37
VISTA, NCT05619471: VIO Imaging for Skin Tissue Assessment

Completed
N/A
65
US
VIO Imaging
Enspectra Health, National Cancer Institute (NCI), National Institutes of Health (NIH)
Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities, Skin Cancer
08/23
08/23
NCT03853486: ATHN 9: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
NCT05568459: A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Recruiting
N/A
120
Europe, Canada, US
Non-Interventional
Regeneron Pharmaceuticals
Hemophilia B
04/26
04/26
Kadia, Tapan M
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
NCT04496349: A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL

Recruiting
2
36
US
APG-115, APG-2575
Ascentage Pharma Group Inc.
T-Prolymphocytic Leukemia
05/24
05/25
NCI-2019-04987, NCT04062266: AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Recruiting
2
50
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Genentech, Inc.
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia, Minimal Residual Disease Persistence, Therapy-Related Acute Myeloid Leukemia
10/30
10/30
NCT04358393: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Recruiting
1/2
69
US
APG-115, 5-azacitidine, Vidaza, Azadine
Ascentage Pharma Group Inc.
AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
12/24
12/25
NCT04964518: A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Recruiting
1/2
24
US, RoW
APG 2575 ramp up arm, APG2575
Ascentage Pharma Group Inc.
AML, Adult
07/24
10/24
NCT05532722: ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Recruiting
1/2
30
US
ABC008
Abcuro, Inc.
T-cell Large Granular Lymphocytic Leukemia
12/24
12/25
NCT04409080: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

Recruiting
1/2
33
Europe, US, RoW
REGN7257
Regeneron Pharmaceuticals
Severe Aplastic Anemia (SAA)
01/26
05/26
NCT03537482: APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Recruiting
1
90
US, RoW
APG-2575
Ascentage Pharma Group Inc.
Hematologic Malignancies
09/24
02/25
NCT03773393: A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Active, not recruiting
1
18
US
CK0801
Cellenkos, Inc.
Bone Marrow Disease
05/24
05/24
Pant, Shubham
KEYNOTE-823, NCT03637803: Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Checkmark Interim Results from the Phase I/II Study of MRx0518 and KEYTRUDA for Renal Cell Carcinoma
Mar 2022 - Mar 2022: Interim Results from the Phase I/II Study of MRx0518 and KEYTRUDA for Renal Cell Carcinoma
Checkmark Comprehensive clinical benefit data from part A in combination with MRx0518 in solid tumors
Aug 2020 - Aug 2020: Comprehensive clinical benefit data from part A in combination with MRx0518 in solid tumors
Checkmark Safety data from Part A of study in combination with MRx0518
More
Terminated
1/2
63
US
MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA], MK3475, Pembrolizumab, Keytruda
4D pharma plc, Merck Sharp & Dohme LLC
Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
05/23
05/23
NCT04731467: A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Checkmark Presentation of data in combination with CM24 for solid tumors at AACR 2022
Apr 2022 - Apr 2022: Presentation of data in combination with CM24 for solid tumors at AACR 2022
Checkmark Initiation of trial in combination with Opdivo for NSCLC
Feb 2021 - Feb 2021: Initiation of trial in combination with Opdivo for NSCLC
Active, not recruiting
1/2
79
Europe, US, RoW
CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion
Famewave Ltd., Bristol-Myers Squibb
Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
12/24
01/25
NCT06208124: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Recruiting
1/2
240
US
IMM-6-415
Immuneering Corporation
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
06/27
07/27
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/25
04/25
NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Recruiting
1/2
156
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
AMPLIFY-201, NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Active, not recruiting
1
25
US
ELI-002 2P
Elicio Therapeutics
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
01/23
03/26
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
Odisio, Bruno
NCT04107766: NOLA (NeuWave Observational Liver Ablation) Registry

Recruiting
N/A
1500
Europe, US, RoW
Microwave Ablation
Ethicon, Inc.
Cancer of the Liver, Liver Cancer, Neoplasms, Liver
12/27
12/27
Brander, Danielle M
NCT04305444: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Recruiting
2
120
US
DTRM-555, DTRMWXHS-12, everolimus, pomalidomide
Zhejiang DTRM Biopharma
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation
03/24
03/24
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
209
US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT03537482: APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Recruiting
1
90
US, RoW
APG-2575
Ascentage Pharma Group Inc.
Hematologic Malignancies
09/24
02/25
NCT04704323: CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Recruiting
N/A
25
Europe, US
CAP-100
Catapult Therapeutics
Lymphocytic Leukemia, Chronic, SLL
01/25
04/25
Patel, Krina
NCT05855967: A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Active, not recruiting
4
250
RoW
Ixekizumab, LY2439821
Eli Lilly and Company
Plaque Psoriasis, Psoriatic Arthritis
07/24
09/24
Linderman, Debra Bull -
NCT04964518: A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Recruiting
1/2
24
US, RoW
APG 2575 ramp up arm, APG2575
Ascentage Pharma Group Inc.
AML, Adult
07/24
10/24
Johnson, Benny
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
STOPTRAFFIC-1, NCT04599140: SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the Trial

Recruiting
1/2
53
US
CXCR1/2 Inhibitor SX-682, SX 682, SX-682, SX682, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, Bristol-Myers Squibb, Syntrix Biosystems, Inc.
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
01/25
01/25

Download Options